tirzepatide patent news Challenged Again! Why Generic Tirzepatide Won't Be

Furthermore, the Wnt/-catenin pathway and the renin-angiotensin system (RAS), which generates ROS [64], create a cycle of ongoing glomerular damage [65]

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist that has transformed metabolic disease treatment

The most common side effects are gastrointestinal, including nausea, diarrhea, and vomiting, though fatigue is documented in the labeling

Hypoglycemia was less common with tirzepatide than with insulin degludec

In Quebec, where one in four adults is obese, the current cost of these new drugs (approximately $500 per month) would involve an annual expenditure of several hundred million dollars (in the United States the situation is even worse: the cost of a 72-week course of tirzepatide (15 mg/week) is approximately US$17,000, while the 68-week treatment with semaglutide (2.4 mg/week) is nearly US$23,000!)